Medicus Pharma receives UAE approval for Phase 2a Endometriosis trial
Last updated: 11:20 31 Jul 2026 EDT, First published: 10:20 31 Jul 2026 EDT
Medicus Pharma Chief Medical Officer Dr Faisal Mehmud joined Steve Darling from Proactive to discuss the company's receipt of Investigational New Drug (IND) authorization from the United Arab Emirates Department of Health – Abu Dhabi for its PRECISION-E2 Phase 2a clinical trial evaluating Teverelix® in women with moderate-to-severe symptomatic endometriosis.
Mehmud said the authorization follows the Department of Health's comprehensive review of the company's chemistry, manufacturing and controls (CMC), non-clinical, clinical, and safety data, resulting in approval for the study to proceed, subject to final site-specific Institutional Review Board and ethics approvals.
The PRECISION-E2 trial is a prospective, randomized, placebo-controlled Phase 2a study that will enroll approximately 84 women across multiple investigational sites in the UAE. The study will evaluate the pharmacodynamics, safety, tolerability, clinical activity, and exploratory genomic biomarkers of Teverelix®, a long-acting GnRH antagonist.
Management believes the study marks an important milestone in its women's health strategy and positions Teverelix® among the first genomics-guided precision medicine programs designed to identify women with endometriosis who are most likely to benefit from targeted therapy.
Endometriosis is a chronic estrogen-dependent inflammatory disease affecting approximately one in ten women of reproductive age worldwide, and Medicus believes the PRECISION-E2 study could help advance a more personalized treatment approach for patients with moderate-to-severe disease.
#proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #ClinicalTrials #Phase2 #Teverelix #Endometriosis #ClinicalTrials #WomensHealth #PrecisionMedicine #Biotech #DrugDevelopment #HealthcareInnovation #Phase2Trial
